Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer

Abstract excerpt

PURPOSE: Topoisomerase IIalpha (Topo II) is a potential marker of responsiveness to anthracycline-based therapy. We analyzed the role of Topo II gene status in the prediction of pathological complete remission (pCR) after primary anthracycline-based chemotherapy in non- endocrine responsive breast cancers overexpressing Her2/neu. METHODS: Twenty-three patients, with T2-T4, ER and PgR absent, overexpressing...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Cancer Treatment Studies
• Share to Cancer therapeutics and mechanisms
• Share to HER2/EGFR in Cancer Research